Inquis Medical Raises $75 Million Series C From Strategic Investor for AVENTUS Thrombectomy

Inquis Medical, a privately held Menlo Park, California, company that makes a mechanical thrombectomy system for blood clots in the veins and lungs, announced the closing of a $75 million Series C financing round on Monday, January 12, in a release distributed by Business Wire and read via BioSpace. The money came from a single strategic investor that the company did not name.

The company said the funds will be used to accelerate the nationwide commercial expansion of its AVENTUS Thrombectomy System and to advance its next-generation product pipeline. It plans to expand its sales and physician-training infrastructure while continuing to build its clinical evidence base.

Inquis did not disclose a valuation or say what kind of company the strategic investor is.

From Series B to Series C

The Series C builds on a $40 million Series B round led by Marshall Wace that closed in August 2024, according to the release. Inquis, founded in 2020, said 2025 was the year it became a commercial-stage company.

"The successful closing of our Series C financing marks a pivotal inflection point for Inquis Medical as we scale our footprint in the VTE market," said Vahid Saadat, the company's co-founder and co-chief executive.

Mojgan Saadat, also a co-founder and co-chief executive, called the round "a strong endorsement of our commercial trajectory and the clinical progress our team has achieved."

The AVENTUS system

In June 2025, Inquis announced that AVENTUS had received FDA 510(k) clearance for an expanded indication to treat pulmonary embolism, Endovascular Today reported. The device had previously been cleared for use in the peripheral vasculature.

The system combines directional aspiration with in-line reinfusion of the patient's own blood, which the company said is meant to remove clot efficiently while reducing blood loss. Inquis also said the system uses proprietary tissue-sensing technology that gives operators real-time feedback to tell blood, clot and vessel wall apart, along with an atraumatic dilator tip and an integrated navigation catheter.

Results from the AVENTUS pivotal trial in 130 patients with intermediate-risk pulmonary embolism were presented at the Society for Cardiovascular Angiography & Interventions 2025 scientific sessions and published in the society's journal, JSCAI, Endovascular Today reported. The company said the published data showed significant thrombus removal while limiting blood loss, with no device-related adverse events.

The company describes AVENTUS as its flagship product and says it is designed to address the procedural complexity of large-vessel thrombectomy, including in pulmonary embolism. The release did not give sales figures for the system.